NCT06641024View on ClinicalTrials.gov

Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 1, 2024

Primary Completion Date

November 1, 2027

Study Completion Date

November 1, 2039

Conditions
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

MC-1-50

A single infusion of CD19 CAR-T cells will be administered intravenously after lymphodepletion chemotherapy

Trial Locations (1)

Unknown

Rui Jin hospital, Shanghai Jiao Tong university school of medicine, Shanghai

All Listed Sponsors
collaborator

Ruijin Hospital

OTHER

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY

NCT06641024 - Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | Biotech Hunter | Biotech Hunter